Malta - angleščina - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - milrinone - solution for infusion or injection - milrinone 1 mg/ml - cardiac therapy

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

max health limited - milrinone 1 mg/ml - concentrate for injection - 1 mg/ml - active: milrinone 1 mg/ml excipient: glucose lactic acid sodium hydroxide water for injection - milrinone is indicated for the short term intravenous therapy of severe congestive heart failure. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - milrinone - solution for injection/infusion - 1 milligram(s)/millilitre - phosphodiesterase inhibitors; milrinone

Irska - angleščina - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - milrinone - solution for injection/infusion - 1 milligram(s)/millilitre - phosphodiesterase inhibitors; milrinone

Združene države Amerike - angleščina - NLM (National Library of Medicine)

fresenius kabi usa, llc - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure.  patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment.  the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available.  the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics.  there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection is contraindicated in patients who are hypersensitive to it.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

gland pharma limited - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection is contraindicated in patients who are hypersensitive to it.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hospira, inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone is contraindicated in patients who are hypersensitive to it.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection is contraindicated in patients who are hypersensitive to it.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

gland pharma limited - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone is contraindicated in patients who are hypersensitive to it. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

eugia us llc - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate in 5% dextrose injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone is contraindicated in patients who are hypersensitive to it. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.